Andrew James King - 06 Oct 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Role: Chief Scientific Officer
Signature: /s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 06 Oct 2022
Net transactions value: -$70,044
Form type: 4
Filing time: 11 Oct 2022, 16:32:28 UTC
Previous filing: 05 Aug 2022
Next filing: 04 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KDNY	Common Stock	Options Exercise		+10,152	+172%		16,049	06 Oct 2022	Direct	F1
transaction	KDNY	Common Stock	Sale	$70,044	-3,557	-22%	$19.69	12,492	06 Oct 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KDNY	Restricted Stock Units (RSU)	Options Exercise	$0	-10,152	-50%	$0.000000	10,152	06 Oct 2022	Common Stock	10,152		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F4	The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date.